-
A falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection has been found supplied through one online pharmacy in the UK. The falsified product is labelled with batch D873576 and applies to Mounjaro Kw…
-
Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioration in vision, usually in one eye at a time, has been very rarely reported in association with semaglutide in the treatmen…
-
The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk o…
-
There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, which have different stated mg doses but are bioequivalent, will both …
-
The annual #MedSafetyWeek campaign takes place from 3 to 9 November 2025. This year’s campaign theme is ‘we can all help make medicines safer.’
-
Patients should be reminded and reassured that there is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol is recommended as the first-choice pain reliever for pregnant women, used at…
-
Healthcare professionals should be aware of the potential risk of pulmonary aspiration in patients using GLP-1 or dual GIP/GLP-1 receptor agonists who undergo surgery or procedures with general anaesthesia or deep sedation.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. 
-
Healthcare professionals are reminded to inform patients about the common and serious side effects associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs).
-
We ask healthcare professionals to support new guidance for users of diabetes management equipment, their families, care givers and representatives.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices, and information about the publication of two recent Device Safety Information pages. The article also includ…
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
Falsified, potentially harmful Ozempicâ–¼ and Saxenda products have been found in the UK.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines, and a recent National Patient Safety Alert highlighting the risk of deaths and serious injuries from entrapment or falls relatin…
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices and a reminder of a recent MHRA National Patient Safety Alert to highlight the potential risk of underdosing …
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices and details of two recent MHRA National Patient Safety Alerts to remove from service Philips Health Systems V…
-
Risk minimisation materials are available to support the safe use of new paediatric formulations of rivaroxaban (Xarelto) and dabigatran etexilate (Pradaxa). In addition, we ask healthcare professionals to consult the curren…
-
We remind healthcare professionals that accidental use of glucose-containing solutions as flush fluid for arterial lines may contaminate blood samples and result in falsely high glucose readings. This may lead to inappropria…
-
A summary of recent letters and notifications sent to healthcare professionals about medicines.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
Premature puberty and genital enlargement have been reported in children who were in close physical contact with an adult using topical testosterone and who were repeatedly accidentally exposed to this medicine. To reduce th…
-
A summary of recent letters and notifications sent to healthcare professionals about medicines.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines, and a patient safety alert on mexiletine hydrochloride.
-
Decreased vitamin B12 levels, or vitamin B12 deficiency, is now considered to be a common side effect in patients on metformin treatment, especially in those receiving a higher dose or longer treatment duration and in those …
-
We have issued a National Patient Safety Alert following serious reports of harm associated with insulin leakage during use of the Accu-Chek Insight Insulin pump with NovoRapid PumpCart prefilled insulin cartridges. Patients…
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. Includes a recent recall of Accupro (quinapril hydrochloride) and advice on Xagrid (anagrelide hydrochloride…
-
A large study has shown no safety issues of concern relating to the use of metformin during pregnancy. The licence for metformin now reflects that it can be considered for use during pregnancy and the periconceptional phase …
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
The authorisation holder for dapagliflozin has withdrawn the indication for type 1 diabetes mellitus. The removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapaglifl…
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals
-
A summary of letters and drug alerts recently sent to healthcare professionals.
-
A summary of letters and recent medicine recalls and notifications sent to healthcare professionals.
-
If a patient reports persistent symptoms when switching between different levothyroxine tablet formulations, consider consistently prescribing a specific product known to be well tolerated by the patient. If symptoms or poor…
-
A summary of letters and recent medicine recalls and notifications sent to healthcare professionals.
-
A summary of letters and recent medicine recalls and notifications sent to healthcare professionals.
-
When children receiving replacement therapy for adrenal insufficiency are being switched from hydrocortisone tablets to Alkindi granules, parents or carers should be informed of the need to be extra vigilant for symptoms of …
-
A summary of letters and drug alerts recently sent to healthcare professionals.
-
A summary of letters and drug alerts recently sent to healthcare professionals.
-
Cutaneous amyloidosis at the injection site has been reported in patients using insulin and this may affect glycaemic control. Remind patients to rotate injection sites within the same body region.
-
Evaluate a patient’s individual factors for benefits and risks before initiating treatment with denosumab 60mg, particularly in those with previous vertebral fracture. Patients should not stop denosumab without specialist re…
-
A summary of letters and drug alerts recently sent to healthcare professionals, including recommendations to reduce handling errors with leuprorelin-containing depot medicines.